

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipel⦠read more
Healthcare
Biotechnology
29 years
USD
Exclusive to Premium users
$0.81
Price-2.59%
-$0.02
$12.549m
Small
-
Premium
Premium
-328.6%
EBITDA Margin-353.9%
Net Profit Margin-
Free Cash Flow Margin$26.846m
-5.9%
1y CAGR-14.4%
3y CAGR+0.0%
5y CAGR-$49.378m
-25.8%
1y CAGR-12.4%
3y CAGR-12.3%
5y CAGR-$3.16
-23.4%
1y CAGR-5.8%
3y CAGR-7.3%
5y CAGR-$28.592m
$24.462m
Assets$53.054m
Liabilities$18.855m
Debt77.1%
-0.5x
Debt to EBITDA$0.00
+100.0%
1y CAGR+28.1%
3y CAGR+30.3%
5y CAGR